Buspirone Side Effects in the First Week: What to Expect and How to Manage Them
Author:
Blossom Editorial
Mar 11, 2026
Starting a new anxiety medication can feel uncertain, especially when side effects show up before the benefits do. Buspirone is an FDA-approved anxiety medication used for treating generalized anxiety disorder.
It is generally considered to have a more favorable side effect profile than other anxiety medications, such as SSRIs, but the first week can still come with some adjustment symptoms. Knowing what to expect can help you stay the course rather than giving up too early.
Key Takeaways
The most common side effects of buspirone in the first week are dizziness, nausea, headache, and nervousness — all of which are typically mild and tend to improve within one to two weeks as the body adjusts.
Unlike benzodiazepines, buspirone carries a much lower risk of sedation, cognitive impairment, and dependence, though mild drowsiness or dizziness can occur. It’s important to remember that individual responses may vary.
Side effects can arrive before benefits do — anxiety relief typically takes two to four weeks to develop, so managing the early adjustment period is an important part of treatment success.
Why Do Side Effects Happen in the First Week?
When you start buspirone, your brain begins adjusting to its effects on serotonin 5-HT1A receptors and dopamine pathways. Buspirone peaks in the bloodstream roughly 40–90 minutes after a dose, which can temporarily alter serotonin signaling before your receptors have had time to adapt. The early symptoms are thought to reflect temporary adjustments in neurotransmitter signaling as the body adapts to the medication.
The good news: most early side effects are mild and self-limiting. In clinical trials, most people who reported side effects rated them as mild to moderate, and they typically resolved within the first two weeks of treatment.
Most Common Buspirone Side Effects in the First Week
Dizziness and Lightheadedness
Dizziness is the most frequently reported side effect of buspirone. In a study involving over 900 patients with generalized anxiety disorder, dizziness occurred in 9% of buspirone-treated patients compared to 2%% in the placebo group.
In clinical trials cited in the FDA prescribing information, about 12% of patients taking buspirone reported dizziness compared with about 3% taking a placebo.
Some people notice dizziness when changing positions quickly. Moving slowly from sitting or lying to standing can help reduce this sensation. Staying well hydrated also reduces the likelihood of dizziness during the adjustment period.
Nausea and Other Gastrointestinal Side Effects
Nausea is the second most commonly reported early side effect. In early clinical trials, around 8% of subjects on buspirone reported nausea compared to 5% on a placebo.
Diarrhea is another possible gastrointestinal side effect reported in earlier studies as having an incidence rate of 3% vs 1% with placebo.
A systematic review and meta-analysis of clinical trials found that taking buspirone may increase the likelihood of constipation and gastric distress compared to placebo. However, further analysis revealed that these findings may not be consistent.
Taking buspirone with food can help. Since food increases buspirone's bioavailability (how much of it finally reaches the bloodstream in an active form), the key is to be consistent — always take it with food or always without, so your blood levels remain stable.
Headache
Headache was reported in 7% of buspirone-treated patients in early clinical trials compared to 2% in placebo groups. Like dizziness and nausea, headaches tend to improve as the body acclimates during the first two weeks.
Nervousness or Restlessness
Some people experience a paradoxical increase in nervousness or restlessness in the early days of treatment. Based on data from earlier clinical trials, a syndrome of restlessness appearing shortly after starting buspirone has been reported in a small fraction of patients (5%), potentially related to buspirone's mild effects on dopamine receptors.
A recent study published in the Journal of Affective Disorders listed anxiety as a commonly reported side effect of buspirone based on data from the FDAs adverse event reporting system database.
This can feel discouraging when you're taking a medication specifically for anxiety, but it is typically temporary. If restlessness persists beyond one to two weeks, your provider may adjust the dosing schedule or titration pace.
Drowsiness
Drowsiness is often listed as a buspirone side effect, but the clinical data reveal a more nuanced story. An earlier review found that the incidence of drowsiness in buspirone-treated patients (9%) did not differ significantly from placebo (10%).
More importantly, buspirone produced significantly less drowsiness than all the benzodiazepines it was compared to — diazepam (32%), lorazepam (58%), and alprazolam (43%). This is one of buspirone's key advantages for people who need to stay alert during the day.
Paresthesia and Tremors
Paresthesia is a feeling of numbness or tingling (pins and needles) in the extremities. While not a commonly reported side effect of buspirone (1-2%), paresthesia could result from buspirone’s interaction with dopamine receptors or serotonin modulation. If paresthesia persists even after a few weeks, discuss with your doctor.
Tremors are another reported neurological side effect of buspirone. Though early clinical trials recorded an incidence rate of 1% among patients, more recent studies include tremors as one of the more commonly reported buspirone side effects, along with dizziness and anxiety.
If you notice tremors or other movement disorders when on buspirone, contact your prescribing doctor. They may reduce your dosage or switch medications.
What Side Effects Are Not Common With Buspirone
Part of what makes buspirone notable is what it does not typically cause. Unlike many anxiety and antidepressant medications, buspirone is not generally associated with:
Significant sedation or cognitive impairment: you can generally drive and work normally
Weight gain: clinical data show buspirone is weight-neutral, and some studies even suggest slight weight loss in certain groups.
Sexual side effects: in fact, buspirone has been used as an augmentation agent to reduce sexual side effects caused by SSRIs
Physical dependence or withdrawal: this is a fundamental pharmacological difference from benzodiazepines
This favorable side effect profile is part of why buspirone is considered for long-term anxiety management in appropriate patients. However, it must be noted that individual response varies.
When Side Effects During Week One Are Serious
While most first-week side effects are mild, there are rarer reactions that warrant prompt medical attention:
Serotonin syndrome — symptoms include agitation, rapid heart rate, high temperature, muscle twitching or stiffness, and sweating. Risk increases when buspirone is combined with other serotonergic medications like SSRIs. If you experience these symptoms, seek emergency care.
Unusual involuntary movements — Buspirone is not usually associated with movement disorders, unlike benzodiazepines. However, in a few rare cases, movement disorders such as dyskinesia, akathisia, and Parkinsonism have been reported within one month of starting the medication. Contact your provider if these occur.
Allergic reaction — hives, difficulty breathing, or facial swelling require immediate medical attention.
If you are taking Lexapro (escitalopram) or another SSRI alongside buspirone, your provider should be aware of the combination to monitor for serotonin-related symptoms.
How Long Do First-Week Side Effects Last?
Most mild side effects from buspirone improve within one to two weeks as the body adjusts. In a study on long-term buspirone therapy, no new or unexpected side effects appeared in patients who continued treatment for up to one year, suggesting that the adjustment period carries the highest burden of side effects.
The critical thing to remember is that side effects tend to peak before benefits arrive. While side effects may manifest in a few days, it could be two to four weeks before clinically significant anxiety relief becomes apparent. Stopping the medication before it has had enough time to work may reduce the likelihood of benefit.
Tips for Managing Side Effects in the First Week
Take each dose with food and stay consistently hydrated
Move slowly when transitioning from sitting or lying to standing to prevent dizziness
Spread doses evenly throughout the day — three-times-daily dosing can sometimes produce fewer side effects than twice daily
Keep a brief symptom log so you can track patterns and discuss them at your next appointment
Avoid alcohol — it can increase sedation and dizziness
If side effects continue beyond two weeks or become difficult to tolerate, contact your provider. They may adjust your dose, change the titration schedule, or evaluate whether buspirone is the right fit for your situation.
Medical Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or qualified healthcare provider with questions about your medication. If you are experiencing a mental health crisis, call or text 988.
Sources
Wilson TK, Tripp J. Buspirone. [Updated 2023 Jan 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531477/
Newton, R. E., Marunycz, J. D., Alderdice, M. T., & Napoliello, M. J. (1986). Review of the side-effect profile of buspirone. The American journal of medicine, 80(3B), 17–21. https://pubmed.ncbi.nlm.nih.gov/2870641/
U.S. Food and Drug Administration. (2010). BuSpar (buspirone hydrochloride) tablets prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf
Du, Y., Li, Q., Dou, Y., Wang, M., Wang, Y., Yan, Y., Fan, H., Yang, X., & Ma, X. (2024). Side effects and cognitive benefits of buspirone: A systematic review and meta-analysis. Heliyon, 10(7), e28918. https://pmc.ncbi.nlm.nih.gov/articles/PMC11004816
Gammans, R. E., Mayol, R. F., & LaBudde, J. A. (1986). Metabolism and disposition of buspirone. The American journal of medicine, 80(3B), 41–51. https://pubmed.ncbi.nlm.nih.gov/3515929/
Zujun Wen, Xiang Liu, Pei Guo, Chen Wang, Xingxing Xu, & Peng Liu. (2026). Adverse events related to buspirone: A real-world pharmacovigilance study using the FAERS database. Journal of Affective Disorders, 401, 121240. https://www.sciencedirect.com/science/article/abs/pii/S0165032726000911
Rissardo, J. P., & Caprara, A. L. F. (2020). Buspirone-associated Movement Disorder: A Literature Review. Prague medical report, 121(1), 5–24. https://pubmed.ncbi.nlm.nih.gov/32191616/
Tiller J. W. (1989). The new and newer antianxiety agents. The Medical journal of Australia, 151(11-12), 697–701. https://pubmed.ncbi.nlm.nih.gov/2574409/
Rakel R. E. (1990). Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. Southern medical journal, 83(2), 194–198. https://pubmed.ncbi.nlm.nih.gov/2406933/
Sramek, J. J., Hong, W. W., Hamid, S., Nape, B., & Cutler, N. R. (1999). Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety. Depression and anxiety, 9(3), 131–134. https://pubmed.ncbi.nlm.nih.gov/10356651/
Drugs.com. (2025, May 22). Buspirone side effects: Common, severe, long term. https://www.drugs.com/sfx/buspirone-side-effects.html
Mayo Clinic Staff. (2025, July 1). Buspirone (oral route). Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/buspirone-oral-route/description/drg-20062457
National Institute of Mental Health. (2024, December). Anxiety disorders. U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/topics/anxiety-disorders
Sramek, J. J., Tansman, M., Suri, A., Hornig-Rohan, M., Amsterdam, J. D., Stahl, S. M., Weisler, R. H., & Cutler, N. R. (1996). Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. The Journal of clinical psychiatry, 57(7), 287–291. https://pubmed.ncbi.nlm.nih.gov/8666569/
Wishart, D. S., Feunang, Y. D., Guo, A. C., et al. DrugBank 5.0 contributors. (2024). Buspirone (DrugBank ID: DB00490). DrugBank. https://go.drugbank.com/drugs/DB00490
